Now, researchers from USC Viterbi’s Alfred E. Mann Department of Biomedical Engineering and the Keck School of Medicine, in collaboration with researchers at UCLA, have developed a revolutionary solution: a flexible ultrasound-induced wireless implantable (UIWI) stimulator secured to the spine and designed for personalized, self-adaptive chronic pain management.

A novel PET radiotracer can accurately detect a wide range of mold species that are linked to dangerous infections, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting. The imaging agent has the potential to dramatically enhance the diagnosis and monitoring of invasive mold infections in patients.

The FDA has authorized an AI-based brain-mapping software program developed by Eric Leuthardt, MD, the Shi H. Huang Professor of Neurological Surgery at WashU Medicine, to be marketed by Sora Neuroscience, a WashU startup company he founded with other faculty members. The software has the potential to improve neurosurgery procedures for patients.

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, according to results from a pilot clinical study. The agent, ⁶⁸Ga-aGPC3-scFv, coded as XH06, was shown to be safe, well-tolerated, and effective at providing high-contrast images of GPC3-positive liver tumors, offering a promising new tool for early diagnosis and staging of HCC—one of the most lethal forms of liver cancer. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

In a study published this March in PNAS Nexus, researchers at Texas A&M University and Stanford University used a computational model to estimate how smartwatch-based detection could help control the spread of pandemics such as COVID-19 and pandemic influenza.